ArticleBreast cancer research : BCR2025
Ultrasound-guided diffuse optical tomography: an adjunct to ultrasound that can reduce unnecessary breast biopsies.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Convolutional-transformer fusion of ultrasound and diffuse optical tomography for breast lesion classification.Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBreast biopsy is recommended for any lesion in which the radiologist deems the likelihood of malignancy to be greater than 2% and more than 75% of biopsies return with benign results. This study assesses whether the total hemoglobin concentration (HbT) and blood oxygen saturation (%sO2) of malignant and benign breast lesions, obtained using Ultrasound-guided diffuse optical tomography (US-guided DOT), can help reduce benign breast biopsy rates.
methods238 women consecutively recruited were examined with US-guided DOT before their US-guided biopsy. Three or four radiologists independently provided BI-RADS assessments using pre-procedure US and mammography (when available), first without and then with adjunctive US-guided DOT data. Radiologists and study personnel were blinded to biopsy outcomes. HbT and %sO2 were computed and correlated with histopathology. One-way ANOVA test was used on multiple groups followed by a post-hoc Tukey test. Student t-test was performed on any two groups.
results226 women (mean 52 years, 19–85 years) were analyzed, with histopathology showing: 70 invasive carcinomas (grade 3, n = 25, and grade 1&2, n = 45), 7 DCIS, 9 high-risk lesions, and 140 benign lesions. The integration of DOT-derived HbT and %sO2 reduced benign biopsies by 24.54% with a false-negative rate (FNR) of 1.78%. The HbT of the malignancy group (invasive carcinoma and DCIS) was significantly higher than that of all benign lesions (P < 0.001) and the %sO2 was significantly lower than in benign lesions (P = 0.033). The HbT of grade 3 carcinomas was significantly higher than that of grade 1&2 carcinomas (P = 0.042), while the %sO2 was significantly lower (P = 0.015). The HbT of carcinomas smaller than 2 cm (measured by ultrasound ) was not significantly different from that of carcinomas larger than 2 cm (P = 0.781). However, %sO2 differed significantly between these two size groups (P = 0.023).
conclusionsIntegration of HbT and %sO2 into the radiologists’ BI-RADS imaging assessments of ultrasound-visible breast lesions can reduce benign biopsy rates by 25%, while maintaining a FNR below 2%. The correlation of HbT and %sO2 with invasive carcinoma grade, and the size-independent HbT contrast and size-dependent %sO2 level of invasive carcinomas may guide preferential diagnosis of malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.